What is Scilex Holding Co Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Scilex Holding Co's interest expense for the
three
months ended in Dec. 2024 was $ -0.29 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.96 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Scilex Holding Co's Operating Income for the
three
months ended in Dec. 2024 was $ -28.38 Mil. Scilex Holding Co's Interest Expense for the
three
months ended in Dec. 2024 was $ -0.29 Mil.
Scilex Holding Co did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Scilex Holding Co Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co (NAS:SCLX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Scilex Holding Co's Interest Expense for the
three
months ended in Dec. 2024 was $-0.29 Mil. Its
Operating Income
for the
three
months ended in Dec. 2024 was $-28.38 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2024 was $2.37 Mil.
Scilex Holding Co's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as
| Scilex Holding Co did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Scilex Holding Co Business Description
Traded in Other Exchanges
N/A
Address
960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Executives
| Jaisim Shah |
director, officer: See Remarks |
C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560 |
| Henry Ji |
director, officer: Executive Chairperson |
5370 RUETTE DE MER, SAN DIEGO CA 92130 |
| Jay Chun |
director |
C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303 |
| Dorman Followwill |
director |
C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121 |
| Yue Alexander Wu |
director |
C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121 |
| David Lemus |
director |
C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121 |
| Stephen Hoi Ma |
officer: Chief Financial Officer |
C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303 |
| Sclx Stock Acquisition Jv Llc |
10 percent owner |
960 SAN ANTONIO ROAD, PALO ALTO CA 94303 |
| Tommy G Thompson |
director |
7711 CARONDELET, ST. LOUIS MO 63105 |
| Tien-li Lee |
director |
C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303 |
| Sorrento Therapeutics, Inc. |
10 percent owner |
4955 DIRECTORS PLACE, SAN DIEGO CA 92121 |
| Elizabeth Czerepak |
officer: See Remarks |
201 ROUTE 17 NORTH, RUTHERFORD NJ 07070 |
| Laura Hamill |
director |
333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
| Steve Myint |
director |
C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632 |
| Chris Ho |
director, 10 percent owner, officer: Chief Financial Officer |
C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632 |
Scilex Holding Co Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCLX has been successfully added to your 